AVE0010
Total Payments
$10,068
Transactions
13
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $10,068 | 13 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,288 | 4 | 82.3% |
| Unspecified | $1,780 | 9 | 17.7% |
Payments by Type
General
$8,288
4 transactions
Research
$1,780
9 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Randomized, double-blind, placebo-controlled, dose escalation study on safety, pharmacokinetics and pharmacodynamics of lixisenatide in pediatric patients with type 2 diabetes mellitus not adequately | SANOFI US SERVICES INC. | $1,780 | 0 |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $8,288
- SANOFI US SERVICES INC. $1,780
Product Information
- Type Drug
- Total Payments $10,068
- Total Doctors 2
- Transactions 13
About AVE0010
AVE0010 is a drug associated with $10,068 in payments to 2 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2017. In 2017, $10,068 was paid across 13 transactions to 2 doctors.
The most common payment nature for AVE0010 is "Consulting Fee" ($8,288, 82.3% of total).
AVE0010 is associated with 1 research study, including "Randomized, double-blind, placebo-controlled, dose escalation study on safety, pharmacokinetics and pharmacodynamics of lixisenatide in pediatric patients with type 2 diabetes mellitus not adequately" ($1,780).